Back to Search
MARGARET TEMPERO, MD
MD
Internal Medicine Physician
NPI: 1225095730IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G85868(CA)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
G85868(CA)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
G85868(CA)
Education
UNIVERSITY OF NEBRASKA COLLEGE OF MEDICINE
Class of 1977
Research & Publications (20)
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
PMID 12885837·J Clin Oncol·2003
3-trial
High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
PMID 10955789·Clin Cancer Res·2000
3-trial
Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
PMID 18053426·J Natl Compr Canc Netw·2007
6-review
Personalized medicine for pancreatic cancer: a step in the right direction.
PMID 19041649·Gastroenterology·2009
8-other
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
PMID 18815548·Pancreas·2008
4-observational
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
PMID 18539618·Ann Oncol·2008
8-other
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
PMID 18379729·Invest New Drugs·2008
3-trial
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
PMID 18181045·Cancer Invest·2008
3-trial
Workshop on imaging science development for cancer prevention and preemption.
PMID 17655039·Cancer Biomark·2007
8-other
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
PMID 17600091·Ann Oncol·2007
8-other
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
PMID 17363191·Int J Radiat Oncol Biol Phys·2007
3-trial
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
PMID 16957834·Invest New Drugs·2007
3-trial
Pancreatic cancer in mice and man: the Penn Workshop 2004.
PMID 16397208·Cancer Res·2006
7-preclinical
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
PMID 16344320·J Clin Oncol·2006
3-trial
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
PMID 16194453·J Natl Compr Canc Netw·2005
6-review
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
PMID 15999098·Br J Cancer·2005
3-trial
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
PMID 15361643·Int J Gastrointest Cancer·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1600 DIVISADERO ST
SAN FRANCISCO, CA 94115 - Phone
- (415) 353-9888
Quick Facts
- NPI
- 1225095730
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 49
- Publications
- 20
Are you this provider?
Claim Your Profile